Search Results

<< Go back to the Podcast page EPISODE 25: WHAT TO KNOW ABOUT GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA (NEC) Download the transcript here: Podcast Episode 25_Raj .pdf Download PDF • 201KB ABOUT THIS EPISODE What are Grade 3 Poorly Differentiated Neuroendocrine Carcinoma (NEC)? What makes NEC unique? Can a NET transform to NEC? Dr. Nitya Raj from Memorial Sloan Kettering Cancer Center in New York City explains NEC tumor biology and how it guides treatment strategy. She also discusses current clinical trials and research. MEET DR. NITYA RAJ Nitya Raj, MD is a gastrointestinal medical oncologist with a clinical practice devoted to caring for people with gastrointestinal and endocrine cancers, including neuroendocrine tumors, adrenal cancer, colorectal cancer, pancreatic cancer, and other gastrointestinal cancers. Dr. Raj’s research focuses on advancing treatments for neuroendocrine cancers (a rare group of tumors that often begin in the body’s digestive organs as well as adrenocortical cancers. Dr. Raj is also studying ways to improve our understanding of how neuroendocrine tumors change at the genetic level over time and as a result of different treatments, in order to better personalize our care for people with these cancers. Dr. Raj’s work has been recognized and supported by the American Society of Clinical Oncology with a Young Investigator Award and Career Development Award, as well as by the Neuroendocrine Tumor Research Foundation with a Pilot Award. Nationally, Dr. Raj serves on the Neuroendocrine Tumor Task Force of the National Cancer Institute. Dr. Raj is on the faculty of Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College. TOP 10 QUESTIONS What is a poorly differentiated grade 3 neuroendocrine carcinoma (NEC)? Are all NEC poorly differentiated and are all poorly differentiated NEC? Where are they located? How are NEC found? How does one know it is a NEC? How is NEC unique compared to other types of neuroendocrine cancers? In particular, how is it different from grade 3 NET? What types of labs, scans, or testing for NEC? Can a NEC be surgically removed? How would you decide if, when, and how? How are NEC treated medically (or nonsurgically)? What treatment might you use as second-line? What is the role of liver-directed therapy? What is the role of immunotherapy? What are clinical trials we should be aware of or exciting new treatments in the pipeline for NEC? How are NEC monitored? What types of bloodwork or tests should be done and how often should they be done? What words of hope would you like to leave the neuroendocrine cancer community with? RESOURCES Click here for more resources for high-grade >> READ Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms in: Endocrine-Related Cancer Volume 30 Issue 8 (2023) CLINICAL TRIAL SWOG 2012 Trial DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

Lu-177 DOTATATE + Sunitinib in PNETs << Back Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors IDENTIFIER ( ClinicalTrials.gov ) : NCT05687123 DRUG/TREATMENT : Lu177 dotatate + sunitinib study PHASE : 1 STATUS : Recruiting SPONSOR : National Cancer Institute (NCI) DESCRIPTION: This phase I trial tests the safety, side effects, and dosimetry of sunitinib malate in combination with lutetium Lu 177 dotatate in treating patients with pancreatic neuroendocrine tumors. Sunitinib malate is in a class of medications called kinase inhibitors and a form of targeted therapy that blocks the action of abnormal proteins called VEGFRs that signal tumor cells to multiply. This helps stop or slow the spread of tumor cells. Radioactive drugs, such as lutetium Lu 177 dotatate, may carry radiation directly to tumor cells and not harm normal cells. It is also a form of targeted therapy because it works by attaching itself to specific molecules (receptors) on the surface of tumor cells, known as somatostatin receptors, so that radiation can be delivered directly to the tumor cells and kill them. Giving sunitinib malate and lutetium Lu 177 dotatate in combination may be safer and more effective in treating pancreatic neuroendocrine tumors than giving either drug alone. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT : Principal Investigator: Nikolaos Trikalinos,Yale University Cancer Center LAO RELATED RESOURCES Clinical Trials Using Lutetium Lu 177 Dotatate - NCI

< Back to the supporters page << Previous Next >> ABOUT TERSERA TerSera Therapeutics LLC acquires and develops specialty pharmaceutical products with a focus on select therapeutic areas. Our focus is to bring intelligent solutions to prescribers and patients who need better solutions. We deliver a comprehensive set of programs that go beyond the therapy itself in order to provide improved outcomes for patients. Our products make a difference for patients and provide solutions for prescribers. Learn more at www.tersera.com . Talk to a NET nurse about carcinoid syndrome diarrhea. Go to www.enrollxermelo.com . This information is for educational purposes only and does not substitute for medical advice or constitute an endorsement by the Neuroendocrine Cancer Foundation. Talk to your medical team about your individual care and treatment.

< Back to the upcoming events page Learn about the latest in high grade neuroendocrine neoplasms and small cell lung cancer with medical oncologist Dr. Aman Chauhan, Leader of the Neuroendocrine Tumor Program and Co-Director of the Theragnostic Program at the Sylvester Comprehensive Cancer Center, University of Miami. ABOUT DR. AMAN CHAUHAN Aman Chauhan, MD, earned his medical degree from the Kasturba Medical College in Manipal, Karnataka, India, followed by a dual residency in internal medicine and pediatrics at Louisiana State University in New Orleans. Dr. Chauhan completed his fellowship in hematology and oncology at the University of Kentucky, especially focusing on neuroendocrine tumor (NETs). Additionally, Dr. Chauhan completed a Cancer Therapy Evaluation Program (CTEP) physician externship at the National Cancer institute (NCI) that focused on designing clinical trials and clinical research projects. His clinical interests include treating NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small and large cell neuroendocrine carcinoma. Dr Chauhan leads the University of Miami Neuroendocrine Cancer Program and co-leads Sylvester Theranostics Drug Development Program. He is national principal investigator on several investigator initiated neuroendocrine cancer clinical trials. He has authored over 70 scientific publications and book chapters and has received a career development award from NCI CTEP. Dr Chauhan also serves on AJCC and ASCO NET guideline committees and is an active member of NANETS communication committee. Dr. Chauhan is board certified in internal medicine and medical oncology. He is a member of the American Society of Clinical Oncology as well as the American Association of Cancer Research and the North American Neuroendocrine Tumor Society. SPONSORS The information provided is for educational purposes only and does not substitute for medical advice. Talk to your medical team if you have any questions or concerns about your individual care and treatment. The opinions expressed in this program are those of the speakers and do not represent the opinion of LACNETS.

<< Go back to the Podcast page EPISODE 27: WHAT TO KNOW ABOUT NEUROENDOCRINE TUMOR LIVER METASTASES Download the transcript here: LACNETS Podcast Episode 27 Transcript .pdf Download PDF • 206KB ABOUT THIS EPISODE What do you call NETs in the liver? How often do NETs spread and what causes NETs to spread? How do you determine if surgery is an option? Dr. Xavier Keutgen from University of Chicago brings clarity to NET tumors found in the liver and describes how surgery fits in with other treatments for metastatic NETs. MEET DR. XAVIER KEUTGEN Xavier M. Keutgen MD is a board-certified, double-fellowship trained surgeon who specializes in the treatment of gastro, entero, pancreatic neuroendocrine tumors and neoplasms of the thyroid, parathyroid and adrenal glands. A native from Belgium, Dr. Keutgen graduated magna cum laude from the University of Heidelberg Medical School in Germany and completed a general surgery residency and surgical oncology research fellowship at New York Presbyterian Hospital-Weill Cornell Medical Center. He then completed a hepato-pancreato-biliary fellowship at the University Hospital of Zurich in Switzerland as well as an endocrine oncology and surgery fellowship at the National Cancer Institute, National Institutes of Health (NIH) in Bethesda, Maryland. Dr. Keutgen currently serves as the director of the Neuroendocrine Tumor Program, director of the Endocrine Research Program and co-director of the Von Hippel-Lindau Clinical Care Program at the University of Chicago Medicine . Throughout his career Dr. Keutgen has developed a particular interest in clinical, translational and basic science research. His laboratory specializes in investigating the role of radiation therapy and DNA damage repair in pancreatic, lung and small bowel neuroendocrine tumors, discovering new actionable molecular targets for neuroendocrine tumors, and elucidating new mechanisms of drug delivery for endocrine malignancies. TOP TEN QUESTIONS What is liver NETs? How often do NETs spread? Is it expected that NETs will eventually spread? If the primary tumor was already removed, do you now call this liver NET or do you still refer to it by the primary site of origin – and why? How is this different from liver cancer? What causes NETs to spread? Is there anything that is done to cause NET tumors to spread? Is there anything that can be done to keep them from spreading? How do you determine if surgery is an option? What is involved in evaluating metastases? What scans or labs are needed? How do you decide what the “tumor burden” is? How do you weigh the grade or ki67? How do you weigh tumor size? Is there a cut-off for tumor size or the number of tumors that is too much to operate? How does one decide between surgery versus other options? How often can surgery or other treatments be done? How safe is liver surgery? How do you approach surgery for someone with liver tumors who also has tumors in the tail versus the head of the pancreas? When someone has had a Whipple surgery and later is found to have tumors in the liver, what are the options? What advances in the field are you most excited about? RESOURCES LACNETS Surgery Resources WATCH: LACNETS Surgery Playlist DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

Pheo Para < Back to Topics Play Video Play Video 01:07:09 Episode 12: Pheochromocytoma & Paraganglioma (PPGL) ABOUT THIS EPISODE In honor of Pheo Para Awareness Week, NET endocrinologist and medical oncologist Dr. Jaydira Del Rivero of the National Cancer Institute answers ten common questions about pheochromocytoma and paraganglioma (PPGL). Dr. Del Rivero defines PPGL and describes the unique symptoms, genetic testing, and treatment options for PPGL. MEET DR. JAYDIRA DEL RIVERO Dr. Del Rivero earned her medical degree from the University of Veracruz in Veracruz, Mexico and completed her internal medicine residency at Woodhull Medical and Mental Health Center/NYU-Langone Medical Center. Dr. Del Rivero completed a fellowship in Endocrinology, Diabetes and Metabolism at The Inter-Institute Endocrinology Training Program (IETP) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The National Institute of Child Health and Human Development (NICHD), and The National Institute of Dental and Craniofacial Research (NIDCR) where she was part of a research team developing clinical trials for pheochromocytoma and paraganglioma. She then joined as Assistant Professor at the Montefiore Einstein Center for Cancer Care (MECCC) where she specialized in endocrine oncology involving thyroid cancer, parathyroid and adrenal tumors, and clinical research for gastroenteropancreatic neuroendocrine tumors. She subsequently completed a second fellowship in medical oncology at the National Cancer Institute (NCI) with a research focus on endocrine malignancies. Dr. Del Rivero is board certified in Internal Medicine, Endocrinology, Diabetes and Metabolism and Medical Oncology. TOP 10 PPGL QUESTIONS 1. Who should be listening to this podcast episode? Do all NET patients need to know about PPGL? 2. What is PPGL? Is this a cancer? How common is PPGL? How do we know which ones have a higher risk of metastasis? 3. Is this genetic? Who should get genetic testing and when should they get it? Should family members/children get genetic testing or cancer screening? 4. What are the symptoms of PPGL? 5. How is PPGL diagnosed? What labs should be done for PPGL? What scans should I get if have PPGL? Is there a certain priority or order to which scans should get done and when? 6. What is the treatment for PPGL? How do I get appropriate treatment? How do I know what appropriate treatment is? 7. What if my disease is metastatic? What are my treatment options? 8. What if my disease recurs after surgery? What are my treatment options? Could I have surgery again? 9. Will my symptoms be gone after surgery or treatments? 10. I’ve been told I can’t get a biopsy and that surgeries might be dangerous. What do I need to know and what do I need to do? For more resources and a transcript of this episode, visit https://www.lacnets.org/podcast12. Dr. Del Rivero is a Physician Scientist in the Developmental Therapeutics Branch. She is the Principal Investigator of the Natural History Study for Neuroendocrine Neoplasm and Adrenocortical Cancer to provide the basis of further development of therapeutic interventions, prevention/screening guidelines, endpoints for future clinical trials, and patient reported outcome measures. Dr. Del Rivero’s current efforts is the development of novel treatment approaches and targeted therapies for endocrine malignancies such as advanced gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer and pheochromocytoma/paraganglioma. Play Video Play Video 01:42:02 "Focus on Pheochromocytoma and Paraganglioma" - Jan 2023 LACNETS Educational Event Join LACNETS for a Rebroadcast of the unique webinar presentation of three pheochromocytoma and paraganglioma (PPGL) cases and an engaging panel discussion with experts Dr. Jaydira Del Rivero, Dr. Erik Mittra, and Dr. Karel Pacak. (Original broadcast on Wednesday, January 11, 2023) Play Video Play Video 09:47 Caregiver Story - Pheo/Para Aimee Powell, a caregiver and advocate for family members diagnosed with pheochromocytoma and paraganglioma shares what led her to a life of patient advocacy and assisting patients with these rare tumors. Aimee is the founder of The Pheo Para Project – www.pheoparaproject.org. To learn more about LACNETS, visit www.LACNETS.org. Play Video Play Video 01:38:21 LACNETS Webinar: "Update on Pheochromocytoma and Paraganglioma" with Dr. Jaydira Del Rivero Have you wondered if NETs might be hereditary? What do you know about pheochromocytoma and paraganglioma (pheo/para)? NET expert Dr. Jaydira Del Rivero gives a full update on these rare and often misdiagnosed conditions. Recorded on February 17, 2022. To download a copy of Dr. Del Rivero's presentation slides, go to bit.ly/slides_feb2022. This presentation is also available in Spanish, found here: youtu.be/moN-iwvoTsI Speaker: Jaydira Del Rivero, MD, Endocrinologist, Oncologist, National Institute of Health To learn more about LACNETS, visit www.LACNETS.org. < Back to Topics Next Topic >

Save the Date - June 15, 2024 Watch the 2024 LACNETS Neuroendocrine Tumor Patient Conference Play Video Share Whole Channel This Video Facebook Twitter Pinterest Tumblr Copy Link Link Copied Now Playing Welcome and Introductions • 2024 #LACNETS Neuroendocrine Tumor Patient Conference 09:56 Play Video Now Playing "Understanding NET Diagnosis" with Dr. Chandrasekharan • 2024 #LACNETS Patient Conference 35:16 Play Video Now Playing "Understanding NET Scans" with Dr. Nadine Mallak • 2024 LACNETS NET Patient Conference 23:47 Play Video Visit Sponsor Booths Speaker Bios Sponsors THANKS TO OUR SPONSORS Novartis Booth Crinetics Booth IPSEN Booth Curium Booth ABOUT THE CONFERENCE Our 2024 LACNETS Neuroendocrine Tumor Patient Conference is designed for neuroendocrine cancer (NET) patients and caregivers to deepen your understanding of NETs. Whether you are newly diagnosed or have been living with NET for many years, we encourage you to attend: Learn from top NET experts from across North America on a range of topics relevant to the NET patient journey. Topics include work-ups, scans, surgery, carcinoid crisis, liver-directed therapy, PRRT, systemic treatments, treatment sequencing, NET guidelines, and clinical trials. Gain insight into NET decision-making through the NET tumor board panel discussion. Hear stories from NET patients and caregivers. Join virtually, where you can pause, rewind, or replay. There is no cost to attend. This event is made possible by the generosity of donors and sponsors. The information provided is for educational purposes only and does not substitute for medical advice. Talk to your medical team if you have any questions or concerns about your individual care and treatment. The opinions expressed in this program are those of the speakers and do not represent the opinion of LACNETS.

<< Go back to the Podcast page EPISODE 7: IMAGING OF NETS Download a Transcript of this Episode >> ABOUT THIS EPISODE Confused about scans? NET expert Dr. Gary Ulaner answers the top 10 questions about imaging for NETs. Dual board-certified in radiology and nuclear medicine, Dr. Ulaner explains different scans used in NET imaging including functional imaging scans such as Gallium-68 DOTATATE, Copper-64 DOTATATE, and FDG PET scans and anatomical scans such as MRI and CT scans. He addresses common questions about radiation safety, contrasts, and SUV. MEET DR. GARY ULANER Gary A. Ulaner, M.D., Ph.D., F.A.C.N.M. is the Director of Molecular Imaging and Therapy at Hoag Family Cancer Institute. Dr. Ulaner was previously with Memorial Sloan Kettering Cancer Center, where he served as the PET/CT expert on the Breast Cancer Disease Management Team. Dual board-certified in radiology and nuclear medicine, Dr. Ulaner is a nationally recognized expert in the use of targeted imaging to help direct focused cancer therapies. He leads several National Institutes of Health (NIH) clinical trials in molecular imaging and therapeutics, including two active NIH R01 grants, and has received more than $8 million in extramural funding. Dr. Ulaner has received multiple honors throughout his career. He was elected Fellow of the American College of Nuclear Medicine, received an award for breast cancer research from the Susan Komen Foundation, and was the first Hal O’Brien Rising Star from the Society of Nuclear Medicine and Molecular Imaging (SNMMI), among other accolades. Dr. Ulaner has authored or co-authored more than 110 peer-reviewed manuscripts and has given more than 110 clinical presentations, both nationwide and internationally, in addition to writing the textbook Fundamentals of Oncologic PET/CT , published in both English and Spanish. He is also on the editorial boards of several leading clinical journals including: Radiology, Journal of Nuclear Medicine, European Journal of Nuclear Medicine and Molecular Imaging, and Clinical Nuclear Medicine. Dr. Ulaner completed his medical degree and a Ph.D. in Cancer Biology at Stanford University School of Medicine, an internship at Johns Hopkins Hospital, and his Radiology and Nuclear Medicine residencies at the University of Southern California. TOP 10 IMAGING QUESTIONS 1. What is the difference between a DOTATATE PET/CT scan and a FDG PET scan, or the type of PET scans that are commonly ordered for other types of cancers? 2. What is the difference between the Gallium-68 DOTATATE and the newer Copper-64 DOTATATE scans? What are the benefits of one over the other? Should I be getting a Copper-64 scan? 3. I’ve been hearing more about DOTATOC in the US where in the past I've only heard it from European specialists. What is it and are there advantages to DOTATOC vs. DOTATATE? 4. What do SUV values mean on DOTATATE PET Scans? 5. What is the difference between the CT scan in the DOTATATE PET/CT scan and a “regular” CT scan? 6. What type of CT scan should be done to evaluate NET? Should a CT scan be done with contrast? If so, what type of contrast? 7. What is the difference between MRI and CT scan? What type of MRI scan should be done to evaluate NET? Should a MRI scan be done with contrast? If so, what type of contrast? Regarding eovist - the contrast agent of choice, are all the gadolinium agents equal? 8. How concerned should patients be about radiation safety with CT scans, MRI scans, DOTATATE scans, and PRRT? 9. What do you suggest for those of us whose tumors don’t show up on scans? What scan(s) do you do if someone does not have uptake on Ga68 dotatate? What about those whose tumors don’t show up on any scans? 10. What suggestions do you have for patients who are trying to understand their scan report? DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANKS TO OUR SPONSORS

See videos of recent educational events on various topics on neuroendocrine cancer Recent Events "Understanding Treatments for Neuroendocrine Tumors and Rationale for Sequencing of Therapy" April 1, 2025 Learn from internationally-renowned neuroendocrine cancer expert Dr. Edward Wolin in a discussion on the latest in neuroendocrine tumor treatments and understanding how to sequence them. Dr. Wolin has pioneered many of the NET treatments including somatostatin analogues (SSAs, sandostatin and octreotide), mTOR inhibitors (i.e. everolimus), anti-angiogenic drugs (i.e. cabozantinib), and peptide receptor radiotherapy (PRRT, i.e. Lutathera). Listen to this insightful presentation and live question and answer session. Watch NCF Regional NET Patient Educational Event March 29, 2025 The Neuroendocrine Cancer Foundation is hosting an in-person NET Educational Event for patients and caregivers in Tucson, Arizona on Saturday, March 29th, from 1:30-6:00 PM. CLOSED "PRRT Nurse's Perspective: What to Expect with PRRT" March 7, 2025 Learn about PRRT from UCLA's Lead PRRT Nurse Linda Gardner. She addresses common questions about what to expect before, during, and after the treatment, as well as concerns about radiation safety. Watch "Deciphering Genetics & Genomics in Neuroendocrine Cancers" with Dr. Kimberly Perez Feb 7, 2025 Learn the latest in genetics and genomics for neuroendocrine cancers from medical oncologist Dr. Kimberly Perez from Dana Farber Cancer Institute (DFCI) in Boston, Massachusetts. Dr. Perez has expertise in hereditary cancer syndromes and deciphers the topics of genetics and genomics. Watch "Understanding GI NETs Found on Endoscopy: Gastric, Duodenal, Colon & Rectal" with Dr. David Metz Jan 28, 2025 Learn from renowned Neuroendocrinologist Dr. David Metz, who discusses neuroendocrine tumors (NETs) found on endoscopy, including gastric, duodenal, colon and rectal NETs. Dr. Metz discusses which NETs can be found on endoscopies and how they are managed and treated. Watch Comprehensive Guide to Lung Neuroendocrine Cancers: From Typical Carcinoids to Small Cell Lung Cancer (SCLC) Tuesday, Dec 10, 2024 Learn all about lung neuroendocrine cancers from neuroendocrine cancer expert Dr. Aman Chauhan, leader of the Neuroendocrine Tumor Program and Co-Director of the Theragnostic Program at the Sylvester Comprehensive Cancer Center, University of Miami. Dr. Chauhan will give a comprehensive guide to lung neuroendocrine cancers ranging from typical carcinoids to small cell lung cancer. WATCH Palliative Care for Neuroendocrine Cancer Thursday, Nov 14, 2024 Learn about Palliative Care: what it is, what it is not, and how it may help those affected by neuroendocrine cancer. Dr. Chandana Banerjee, palliative care and hospice specialist from the City of Hope Cancer Center in Los Angeles, demystifies these topics. WATCH 2024 NET Cancer Day Symposium Saturday, November 9, 2024 Celebrate with us at the 2024 LACNETS NET Cancer Day Symposium in Santa Monica, California on Saturday, November 9th from 8:30 am - 4:30 pm. WATCH Evolving Management of NET Liver Metastases Friday, October 18, 2024 Hear the renowned liver and pancreas surgeon, Dr. Gagandeep “Gaugs” Singh, discuss the evolving algorithms in managing NET liver metastases. Dr. Singh, Chief of Surgical Oncology at City of Hope® Cancer Center in Phoenix, asks the question of whether it is prudent to be aggressive surgically or if it is all about timing and strategy. Regional NET Patient Education Conference Saturday, September 21, 2024 LACNETS is hosting an in-person NET Educational Event for patients and caregivers in Minneapolis, Minnesota, on Saturday, September 21st, from 1:30-5:00 PM. This event was not live-streamed or recorded. Meet the Expert: Dr. Eric Liu Saturday, August 17, 2024 Join LACNETS in Denver, Colorado for an in-person event. Meet NET expert Dr. Eric Liu who will give a broad survey of NET from diagnosis to treatment and philosophy. Engage in an interactive question and answer session with Dr. Liu. It’s a wonderful opportunity to learn, advocate and connect in-person with a NET expert and fellow NET patients and caregivers. 2024 LACNETS Neuroendocrine Tumor Patient Conference Saturday, June 15, 2024 Join us for the biggest LACNETS event of the year featuring more than ten NET experts. This year's theme is Deepening Your Understanding of NETs. WATCH High Grade Neuroendocrine Neoplasms & Small Cell Lung Cancer Tuesday, May 7, 2024 Learn about the latest in high grade neuroendocrine neoplasms and small cell lung cancer with medical oncologist Dr. Aman Chauhan, Leader of the Neuroendocrine Tumor Program and Co-Director of the Theragnostic Program at the Sylvester Comprehensive Cancer Center, University of Miami. 2024 Updates: Neuroendocrine Cancer Clinical Trials Thursday, April 25, 2024 Learn about the latest in clinical trials for neuroendocrine cancer with NET expert Dr. Heloisa Soares, a medical oncologist at the Huntsman Cancer Institute (HCI) at the University of Utah. TKIs: Tyrosine Kinase Inhibitors & Neuroendocrine Tumors Friday, Mar 29, 2024 Learn about Tyrosine Kinase Inhibitors (TKIs), what they are and how they work with NET expert Dr. Jennifer Chan. Dr. Chan is the Vice President of the North American Neuroendocrine Tumor Society (NANETS) and the principal investigator of the CABINET trial. Hear the positive findings from that TKI study using Cabozantinib. She discusses the latest in TKI treatments and how they may be a possible treatment option for many NET patients. LACNETS Educational Event Feb 14, 2024 Join us to learn about Carcinoid Heart Disease from Cardiologist Dr. S. Allen Luis at the Mayo Clinic in Rochester, MN. He will describe the cause and symptoms of carcinoid heart disease and discuss diagnosis, treatment and surveillance. LACNETS Educational Event "PRRT: What We Know, Special Considerations & Clinical Trials" with Dr. Jonathan Strosberg January 11, 2024 Join us on Thursday, January 11th at 9:30 AM Pacific to learn the latest on PRRT with NET expert Dr. Jonathan Strosberg. Dr. Strosberg was the principal investigator of the NETTER-1 study which led to the FDA approval of Lutathera and has authored numerous articles on PRRT. He will discuss the latest in PRRT, including special considerations and current clinical trials. LACNETS Educational Event "Minimally Invasive Treatments for Neuroendocrine Liver Metastases" with Dr. Yilun Koethe Dec 9, 2023 Join us to learn more about minimally invasive liver-directed therapies targeting liver metastases with interventional radiologist Dr. Koethe. She discusses ablations including the recently approved histotripsy and embolizations including bland, chemo, and radioembolization. LACNETS Educational Event "Symptoms Management" with Dr. David Metz Oct 10, 2023 Join LACNETS to hear Neuroendocrinologist Dr. David Metz from University of Pennsylvania discuss symptom management. The presentation will cover carcinoid syndrome, pancreatic enzymes, bile acid secretion, and short bowel syndrome. He will explain current treatments, supplements, and diets that might be helpful to control NET-related symptoms. LACNETS Educational Event "Navigating Clinical Trials: Expectations Vs. Realities" with Taymeyah Al-Toubah, MPH Aug 19, 2023 Hear Taymeyah Al-Toubah, MPH, Senior Research Project Manager at the Neuroendocrine Tumor Program of Moffitt Cancer Center. LACNETS Educational Event "Surgery: The What, Where & When" with Dr. Eric Liu July 7, 2023 Hear NET expert Dr. Eric Liu of Rocky Mountain Cancer Centers discuss “Surgery: The What, Where & When.” 2023 LACNETS Annual NET Patient Conference June 17, 2023 Watch our biggest event of the year with 12 NET experts from North America. WATCH NOW LACNETS E ducational Event Topic: High Grade Neuroendocrine Neoplasms (NEN) May 4, 2023 Join LACNETS on May 4th for an educational event dedicated to high grade neuroendocrine neoplasms (NENs). Medical oncologist Dr. Jason Starr from Mayo Clinic in Jacksonville, Florida, will discuss the management and treatment of high grade NENs, including the latest updates and clinical trials. LACNETS Educational Event: "What's New in PRRT" April 14, 2023 Join Dr. Amir Iravani, a Nuclear Medicine Physician and Theranostics Director at Fred Hutchinson Cancer Center, to hear the latest on Peptide Receptor Radionuclide Therapy (PRRT). Better understand the difference between beta and alpha PRRT, current trials and updates on PRRT for Lung NET, adolescents and dosimetry. LACNETS Educational Event: "Update on NET Clinical Trials" March 10 , 2023 Join Dr. Heloisa Soares, a medical oncologist at the Huntsman Cancer Institute (HCI) at the University of Utah, to hear the latest in NET clinical trials. LACNETS Educational Event: "Genetics of NET: Do I Need Genetic Testing?" Tuesday, February 7 , 2023 Do I need genetic testing? Do my family members need to be tested? What does genetic testing entail? What genetic mutations are possible and what does it mean for my family if I carry a mutation? Join Genetic Counselor Samantha Greenberg of University of Texas, Southwestern for a discussion about genetic testing for NETs. LACNETS Educational Event : "Novel Translational Research for Metastatic NET Patients at the NCI" Friday, January 27, 2023 Join LACNETS for this special educational event. What if you could both undergo surgery for your metastatic disease and also donate your liver tumor to find a cure for NET? Learn how you can contribute to NET research. The NET team at the National Cancer Institute (NCI) will give us a behind-the-scenes look at their innovative NET research. Be inspired by their hard work and dedication to the NET community. LACNETS Educational Event: Focus on Pheochromocytoma/Paraganglioma Wednesday, January 11, 2023 Join LACNETS for a unique webinar with a live presentation of three pheochromocytoma and paraganglioma (PPGL) cases and an engaging panel discussion with experts Dr. Jaydira Del Rivero, Dr. Erik Mittra, and Dr. Karel Pacak. Click here for our video library for more educational videos

Surgery for NETs Resources EDUCATIONAL WEBINARS "Evolving Management of NET Liver Metastases" with Dr. Singh Watch here "Understanding Surgery for Liver NETs" with Dr. Clarke Watch here "Understanding Carcinoid Crisis" with Dr. Hallet Watch here "A Conversation with Three NET Surgeons" with Dr. Clarke, Dr. Gangi and Dr. Anaya Watch 'A Conversation with Three NET Surgeons' featuring Dr. Callisia Clarke, Dr. Alexandra Gangi and Dr. Daniel Anaya Saenz. This presentation is part of the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference held on June 17, 2023. Watch here "NET Surgery: Making Decisions & Preparing for Surgery" with Callisia Clarke, MD Is surgery the right treatment option for you? Dr. Callisia Clarke joined us for our annual patient conference to address surgery for NETs including decision-making & preparing for surgery. Watch here "Patient Story: How to Prepare for Surgery" NET patient Julie’s “show and tell” of tips, tricks, and specific items she found useful during her hospital stay and recovery at home. Click here for a list of the items Julie mentioned in this video. Watch here Click here for our full surgery video playlist. PODCAST EPISODE 27: WHAT TO KNOW ABOUT NEUROENDOCRINE TUMOR LIVER METASTASES What do you call NETs in the liver? How often do NETs spread and what causes NETs to spread? How do you determine if surgery is an option? Dr Xavier Keutgen from University of Chicago brings clarity to NET tumors found in the liver and describes how surgery fits in with other treatments for metastatic NETs. LISTEN NOW SURGERY FOR NETS To cut or not to cut? A crossroad many neuroendocrine cancer patients are faced with along their journey. NET surgeon Dr. Gagandeep Singh of City of Hope answers the top 10 surgery questions for NETs. LISTEN NOW KEY CONSIDERATIONS FOR NET SURGERY How do surgeons decide the type, extent, and approach of NET surgery? NET surgeon Dr. Alexandra Gangi of Cedars-Sinai answers 10 common questions about what to expect before, during, and after NET surgery. Gain insight on preparing for surgery and what is important for your surgeon to know about your recovery goals. Dr. Gangi’s comprehensive approach illustrates why surgeons are an integral part of your NET medical team. LISTEN NOW ADDITIONAL SURGERY RESOURCES NET Quiz - Test Your Knowledge! How much do you really know about surgery and international radiology for NETs? Test your NET knowledge by taking this six question quiz based off of the NETWise podcast episode #3: “Surgery and Interventional Radiology for NETs.” Take the Quiz Blog Post - Practical Tips for Patients Preparing for Surgery Many NET patients undergo surgery as part of their treatment course. While their medical team might have specific preparation instructions, patients often wonder about practical concerns like how to plan, what to pack, and how to prepare the home... Read the Blogpost

NET Glossary/Index NET Reference Guide for Patients & Families by CNETS Download Here Neuroendocrine Tumors: A Primer for Healthcare Professionals by Healing NET Foundation Download Here

<< Go back to the Podcast page EPISODE 34: NET TREATMENTS: FOCUS ON PRRT Download a Transcript of this Episode >>> ABOUT THIS EPISODE What is PRRT? How is it different from the more commonly used radiation treatment? What are the possible side effects? Dr. Riham El Khouli from the University of Kentucky in Lexington discusses common questions and concerns about PRRT and shares some of the latest advances. MEET DR. RIHAM EL KHOULI, MD, PHD Associate Professor of Radiology, UK College of Medicine Chief, Division of Nuclear Medicine/Molecular Imaging & Radiotheranostics (NM/MI&R) Director, Radiotheranostics Program University of Kentucky Dr. Riham El Khouli, MD PhD, is the director of the Radiotheranostics program and Chief of the division of NM/MI&R at the University of Kentucky and an Associate Professor of Radiology, Nuclear Medicine and Molecular Imaging at UK school of Medicine. The Radiotheranostics Program at UK is a multidisciplinary program that provides state of art standard of care clinical radiopharmaceutical therapy (RPT) techniques as well as a robust research program that constantly runs multiple RPT clinical trials aiming to explore new RPT management options for various cancers. Dr. El Khouli is fellowship trained double board certified, ABR and ABNM, academic Nuclear Radiologist with two decades of clinical and research experience. Her research initially focused on the evaluation and improvement of the acquisition and interpretation of advanced MRI techniques such as dynamic contrast enhanced (DCE) MRI, Diffusion weighted imaging (DWI), and 1H MR Spectroscopy in breast cancer. On 2013, Dr. El Khouli started a new journey in Nuclear Medicine, Molecular Imaging and Radioheranostics (NM/MI&R) and completed a nuclear medicine and dedicated PET/CT fellowships. During her new training, her passion toward molecular imaging and PET/CT grew and she participated in multiple nuclear medicine and PET/CT related research projects. Dr. El Khouli is passionate about research and education and active in the field of neuroendocrine tumor. She is one of the key team members of the dedicated biweekly intramural NET tumor boards. She also attended and presented in multiple regional NANETS and NET awareness group meetings (NCAN). Dr. El Khouli serves as a peer reviewer for multiple prestigious Journals such as Radiology and Radiographics, among others, and is an active member of the Radiologic Society of North America (RSNA), Society of Nuclear Medicine and Molecular Imaging (SNMMI), and the American College of Radiology (ACR). She serves as an active member of the RSNA Awards Committee, RSNA Scientific Abstract Review Committee, and Radiographic NMMI review panel committee. Dr. El Khouli is an active panel member of multiple ACR Appropriateness Criteria Panels. TOP TEN QUESTIONS ABOUT NET TREATMENTS: What is PRRT? How does it work? What is theranostics and what does it mean? What are the terms radiotheranostics, radiopharmaceutical, radioligand therapy, PRRT? How do you determine who is eligible for PRRT? When is PRRT given in one’s treatment journey? How does PRRT differ from other treatments? What are the common side effects of Lutathera? Does Lutathera have long-lasting effects? Would receiving Lutathera affect one’s blood counts? How might Lutathera affect one’s liver function? When, if ever is there concern about liver failure? How might PRRT affect my quality of life and my day-to-day ability to work and function? What is the risk and effects of radiation with receiving Lutathera? What precautions do I need to follow? Can I hug my child? Can I pet my dog? Would receiving Lutathera cause someone to be immunocompromised? How to you decide who should get PRRT? What is peritoneal disease and how effective is PRRT with peritoneal disease? How do you assess the response to PRRT? What advances in PRRT are you most excited about? RESOURCES PRRT Clinical Trials PRRT Resources WATCH May 2024 LACNETS Educational Event with Dr. Aman Chauhan: "High Grade Neuroendocrine Neoplasms & Small Cell Lung Cancer" DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS